Phillip Md Et Al Frost Purchases 150,000 Shares of OPKO Health, Inc. (NASDAQ:OPK) Stock

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost acquired 150,000 shares of the firm’s stock in a transaction on Friday, March 28th. The shares were bought at an average cost of $1.70 per share, for a total transaction of $255,000.00. Following the completion of the acquisition, the chief executive officer now owns 213,651,448 shares of the company’s stock, valued at approximately $363,207,461.60. This represents a 0.07 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Monday, March 17th, Phillip Md Et Al Frost acquired 200,000 shares of OPKO Health stock. The stock was purchased at an average cost of $1.74 per share, with a total value of $348,000.00.
• On Friday, February 28th, Phillip Md Et Al Frost bought 67,434 shares of OPKO Health stock. The stock was acquired at an average cost of $1.71 per share, for a total transaction of $115,312.14.
• On Tuesday, January 28th, Phillip Md Et Al Frost acquired 47,537 shares of OPKO Health stock. The stock was purchased at an average cost of $1.47 per share, with a total value of $69,879.39.
• On Friday, January 17th, Phillip Md Et Al Frost purchased 150,000 shares of OPKO Health stock. The shares were purchased at an average cost of $1.47 per share, for a total transaction of $220,500.00.
• On Wednesday, January 15th, Phillip Md Et Al Frost purchased 500,000 shares of OPKO Health stock. The shares were bought at an average price of $1.48 per share, with a total value of $740,000.00.

OPKO Health Stock Performance

Shares of OPKO Health stock traded down $0.04 on Friday, hitting $1.70. The stock had a trading volume of 2,946,540 shares, compared to its average volume of 4,220,027. The company’s 50 day moving average price is $1.68 and its 200 day moving average price is $1.58. The stock has a market cap of $1.14 billion, a price-to-earnings ratio of -8.95 and a beta of 1.70. The company has a current ratio of 2.97, a quick ratio of 2.69 and a debt-to-equity ratio of 0.30. OPKO Health, Inc. has a 52-week low of $1.12 and a 52-week high of $2.04.

OPKO Health (NASDAQ:OPK) last issued its quarterly earnings data on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.09. The company had revenue of $183.60 million for the quarter, compared to the consensus estimate of $155.42 million. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. On average, research analysts anticipate that OPKO Health, Inc. will post -0.25 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of OPKO Health by 4.5% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 186,783 shares of the biotechnology company’s stock worth $275,000 after buying an additional 8,064 shares in the last quarter. Two Sigma Advisers LP boosted its position in OPKO Health by 2.3% during the fourth quarter. Two Sigma Advisers LP now owns 381,197 shares of the biotechnology company’s stock worth $560,000 after purchasing an additional 8,396 shares in the last quarter. FMR LLC grew its holdings in OPKO Health by 103.6% in the third quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 11,089 shares during the last quarter. Wealth Enhancement Advisory Services LLC increased its holdings in OPKO Health by 75.3% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 28,908 shares of the biotechnology company’s stock valued at $42,000 after acquiring an additional 12,417 shares in the last quarter. Finally, Comerica Bank raised its position in OPKO Health by 18.2% during the fourth quarter. Comerica Bank now owns 106,369 shares of the biotechnology company’s stock worth $156,000 after acquiring an additional 16,369 shares during the last quarter. Institutional investors and hedge funds own 64.63% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on OPK shares. Barrington Research reissued an “outperform” rating and set a $2.25 target price on shares of OPKO Health in a research note on Wednesday, March 12th. HC Wainwright reissued a “buy” rating and issued a $3.00 price objective on shares of OPKO Health in a research report on Wednesday, March 19th. Finally, StockNews.com raised OPKO Health from a “sell” rating to a “hold” rating in a report on Monday, March 3rd.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.